Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · DRREDDY

DR.REDDY'S

HealthcarePharmaceuticals & Biotechnology₹116297 cr market cap
₹1386.30 ▼ -0.85% today As of 19 Nov 2026
52-week low ₹1135.6052-week high ₹1398.20

0.0% from the 52-week high · +23.1% above the low

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 24,832 full-time employees. The Company’s segments include Global Generics, which is engaged in manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and marketing active pharmaceutical ingredients and intermediates for finished pharmaceutical products; Proprietary Products, which focuses on research and development of differentiated formulations and Others, which consists of the Company’s wholly-owned subsidiary, Aurigene Discovery Technologies Limited, which is a discovery stage biotechnology company developing novel and therapies in the fields of oncology and inflammation.

The short version. DR.REDDY'S reported revenue of ₹8,698 crore for Sep 2026, down 1.5% from a year earlier. Net profit was ₹925 crore (down 31.3% year on year). Return on equity was 11.1% in Mar 2026. Promoter holding was 26.63% in Sep 2026, down 0.01 points over 8 quarters.

1 · The price

How has the stock traded?

DR.REDDY'S trades 0.0% at its 52-week high and 23.1% above its 52-week low.

Change over period: —

1M+12.5%
3M+19.5%
6M+5.8%
1Y+12.4%

2 · The business

Is it growing?

Sales, year on year-1.5%

Sep 2026 revenue of ₹8,698 cr.

Profit, year on year-31.3%

Sep 2026 net profit of ₹925 cr.

Net margin10.6%

4.7 pts lower than a year earlier.

3-year growth-2.4% profit

Revenue compounded at 10.9% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue86988100754687538828857285288381
Net profit92544422112101347141815931414
Net margin %10.65.52.913.815.316.518.716.9
EPS (₹)11.085.322.6514.516.1416.9919.0916.94

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue3370032644280112467021545190481751715448
Net profit41965655557845072182195220261950
Net margin %12.517.319.918.310.110.211.612.6
EPS (₹)50.2767.7766.8754.1326.2323.4724.3823.48

3 · The quality

How well does it turn capital into profit?

Return on equity was 11.1% in Mar 2026; debt to equity is 0.17.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %11.116.919.719.4
Return on capital %13.921.825.125.9
EBITDA margin %22.328.630.528.8
Net margin %12.016.819.317.5

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR10.9%12.6%
Profit CAGR-2.4%16.5%
Debt to equity0.17
Interest cover15.4x
Current ratio1.80
P/E ratio41.3

4 · The owners

Who holds it, and are they adding?

Promoter holding26.63%

Down 0.01 pts over 8 quarters.

Foreign institutions31.39%

Down 8.69 pts over 8 quarters.

Domestic institutions31.88%

Up 8.98 pts over 8 quarters.

Mutual fund schemes301

+61 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter26.6426.6426.6426.6426.6426.6326.6426.63-0.01
FII40.0837.2936.3635.5233.233.0832.0731.39-8.69
DII22.925.6226.7427.9830.4430.7231.7431.88+8.98
Public10.2210.1510.09.619.479.339.359.9-0.32

Mutual fund holdings · Oct 2026

301 schemes hold this stock

240 the month before.

  • ICICI Prudential Healthcare Fund9.64% of NAV
  • ICICI Prudential Nifty Pharma ETF8.15% of NAV
  • Nippon India Nifty Pharma ETF8.15% of NAV
  • ICICI Prudential Nifty Pharma Index Fund8.15% of NAV
  • ICICI Prudential Nifty Healthcare ETF7.15% of NAV
  • Axis NIFTY Healthcare ETF7.15% of NAV
  • DSP Nifty Healthcare ETF7.15% of NAV
  • DSP Nifty Healthcare Index Fund7.15% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for DR.REDDY'S are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about DR.REDDY'S

What is the DR.REDDY'S share price?

DR.REDDY'S (DRREDDY) last closed at ₹1,386.30, down 0.85% on the day. Its 52-week range is ₹1,135.60 to ₹1,398.20.

What is the market cap of DR.REDDY'S?

DR.REDDY'S has a market capitalisation of about ₹116,297 crore. Its price-to-earnings ratio is 41.3.

How are DR.REDDY'S's latest results?

DR.REDDY'S reported revenue of ₹8,698 crore for Sep 2026, down 1.5% from a year earlier. Net profit was ₹925 crore (down 31.3% year on year). Return on equity was 11.1% in Mar 2026. Promoter holding was 26.63% in Sep 2026, down 0.01 points over 8 quarters.

Who owns DR.REDDY'S?

As of Sep 2026, shareholding was: Promoter 26.63%, FII 31.39%, DII 31.88%, Public 9.9%.

How many mutual funds hold DR.REDDY'S?

301 mutual fund schemes held DR.REDDY'S in October 2026. That compares with 240 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 10 Jul 2026 · Final Dividend - Rs. 8
  • 10 Jul 2025 · Final Dividend - Rs. 8
  • 28 Oct 2024 · Stock Split From Rs.5/- to Rs.1/-
  • 16 Jul 2024 · Final Dividend - Rs. 40
  • 11 Jul 2023 · Final Dividend - Rs. 40
  • 11 Jul 2022 · Final Dividend - Rs. 30

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.